Clinics in Dermatology
Volume 28, Issue 1 , Pages 67-72 , January 2010

Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies

  • Luigi Naldi, MD

      Affiliations

    • Corresponding Author InformationTel.: +39 0352278719; fax: +39 0352278676.
    web address

References 

  1. Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol. 2006;126:1438–1440
  2. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25:529–534
  3. Feinstein AR. Clinical judgement revisited: the distraction of quantitative models. Ann Intern Med. 1994;120:799–805
  4. Feinstein AR. An additional basic science for clinical medicine: IV. The development of clinimetrics. Ann Intern Med. 1983;99:843–848
  5. Fries JF. Toward an understanding of patient outcome measurement. Arthritis Rheum. 1983;26:697–704
  6. Last JM. A dictionary of epidemiology. New York: Oxford University Press; 1988;
  7. Guyatt GH, Kirshner B, Jaeschke R. Measuring health status: what are the necessary measurement properties?. J Clin Epidemiol. 1992;45:1341–1345
  8. Farber EM, Nall L. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148:1–18
  9. Henseler T, Wolff K, Hönigsmann H, Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet. 1981;1:853–857
  10. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978;157:238–244
  11. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol. 2004;151:381–387
  12. Fleischer AB, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol. 1999;26:210–215
  13. Louden BA, Pearce DJ, Lang W, Feldman SR. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10:7
  14. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51:563–569
  15. Henseler T, Schmitt-Rau KA, comparison between BSA. PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol. 2008;47:1019–1023
  16. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol. 2000;142:728–732
  17. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat. 2004;15:27–29
  18. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141:185–191
  19. Katz S. The science of quality of life. J Chron Dis. 1987;40:459–463
  20. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59–65
  21. Finlay AY. Quality of life measurement in dermatology: a practical guide. Br J Dermatol. 1997;136:305–314
  22. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995;75:240–243
  23. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210:194–199
  24. European Medicines Agency (EMEA) Committee for Proprietary Medicinal Products . Note for guidance on clinical investigation of medical products indicated for the treatment of psoriasis. CPMP/EWP 2454/02 http://www.emea.europa.eu/pdfs/human/ewp/245402en.pdf
  25. McHenry PM, Doherty VR. Psoriasis: an audit of patients' views on the disease and its treatment. Br J Dermatol. 1992;127:13–17
  26. Marks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol. 1989;125:235–240
  27. Naldi L. Dermatology. In:  Day S,  Green SB,  Machin D editor. Textbook of clinical trials. New York: John Wiley & Sons; 2004;
  28. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300:230–235
  29. Brewin CR, Bradley C. Patient preferences and randomized trials. Br Med J. 1989;299:313–315
  30. Nijsten T, Looman CW, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol. 2007;143:1113–1121
  31. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol. 1992;21:837–841
  32. Kendler KS. Toward a scientific psychiatric nosology: strengths and limitations. Arch Gen Psychiatry. 1990;47:969–973
  33. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324
  34. Stucki G, Boonen A, Tugwell P, Cieza A, Boers M. The World Health Organisation International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. J Rheumatol. 2007;34:600–606

PII: S0738-081X(09)00047-9

doi: 10.1016/j.clindermatol.2009.03.001

Clinics in Dermatology
Volume 28, Issue 1 , Pages 67-72 , January 2010

Article Tools

* Image Usage & Resolution